Bevacizumab in Combination With Radiotherapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme

BACKGROUND. Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent. Bevacizumab (BV) may increase resp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: van Linde, Myra E., Verhoeff, Joost J.C., Richel, Dirk J., van Furth, Wouter R., Reijneveld, Jaap C., Verheul, Henk M.W., Stalpers, Lukas J.A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2015
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319643/
https://ncbi.nlm.nih.gov/pubmed/25582142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0418
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi